Pet Drug Reports

Drugs by active ingredient › Dimethyl Sulfoxide + Fluocinolone Acetonide

Drug · combination of 2 active ingredients

Dimethyl Sulfoxide + Fluocinolone Acetonide: adverse event reports

All products with this ingredient combination · 2 FDA-approved applications in the Green Book

348reports naming this combination, 1996–20260% of all reports · about 12 a year
12reports, 12 months to March 20264 in the 12 months before
49.1%classed serious, as reportedof 110 reports stating it
1.7%record death or euthanasia, as reported6 reports
28.7%of reports concern dogs0% of all dog reports

FDA has received 348 adverse event reports in which a drug is recorded with the combination dimethyl sulfoxide and fluocinolone acetonide as its active ingredients, from September 1996 to March 2026. The Green Book lists 2 FDA-approved applications with exactly this combination.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient combination across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 12 reports named it, up 200% from 4 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 12 reports a year and 0% of all 1,357,245 reports (0% of all dog reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

The most frequently coded terms are vials, Leaking (35.6%), accidental exposure (8.9%) and caps, Abnormal (7.8%). A report can list several signs, so shares add to more than 100%; 288 different terms appear across these reports.

28.7% of reports concern dogs. Not every report describes illness: 54.9% as product or packaging defects. Of reports that state seriousness, 49.1% were classed as serious, and 1.7% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog20 · peak 2
Jun 2021: 1Jul 2021: 1Aug 2021: 2Dec 2021: 1Jan 2022: 1May 2022: 1Feb 2023: 2Mar 2023: 1Sep 2023: 1Sep 2024: 1Oct 2024: 1Feb 2025: 1Apr 2025: 1May 2025: 1Jul 2025: 1Nov 2025: 1Mar 2026: 22022202320242025
Cat2 · peak 1
Aug 2021: 1Nov 2024: 12022202320242025
Horse0 · peak 1
2022202320242025
Other17 · peak 3
May 2021: 1Jul 2021: 1Aug 2021: 1Sep 2021: 1Dec 2021: 1Mar 2022: 2May 2022: 1Mar 2023: 2May 2023: 1May 2025: 1Aug 2025: 3Sep 2025: 1Nov 2025: 12022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

022441996: 119961997: 11998: 51999: 719992000: 132001: 142002: 4420022003: 392004: 42005: 1420052006: 82007: 82008: 1420082009: 132010: 152011: 420112012: 102013: 112014: 1720142015: 52016: 122017: 1220172018: 152019: 112020: 920202021: 142022: 52023: 720232024: 32025: 112026: 22026

2026 covers reports received through March 2026 only.

Signs listed in reports

share of dimethyl sulfoxide + fluocinolone acetonide reports listing the termall dog reports

  1. Vials, Leaking[a product quality report, not a sign in an animal]35.6%124
  2. Accidental exposure[exposure that was not intended]8.9%31
  3. Caps, Abnormal[a product quality report, not a sign in an animal]7.8%27
  4. Seal, Abnormal[a product quality report, not a sign in an animal]4.9%17
  5. Lethargy[unusually tired or inactive]4.6%16
  6. Vomiting4.3%15
  7. Lack of efficacy - NOS[the product did not have the expected effect]4%14
  8. Unclassifiable adverse event[event that fits no dictionary term]4%14
  9. Underfilling, Vials[a product quality report, not a sign in an animal]4%14
  10. Anorexia[not eating]3.2%11
  11. Containers, Damaged[a product quality report, not a sign in an animal]3.2%11
  12. Eye pain3.2%11
  13. Vials, Damaged[a product quality report, not a sign in an animal]2.9%10
  14. Polydipsia[drinking more than usual]2.6%9
  15. Anaemia NOS[low red blood cell count]2%7
  16. Behavioural disorder NOS[behaviour change, type not specified]2%7
  17. Containers, Leaking[a product quality report, not a sign in an animal]2%7
  18. Diarrhoea[diarrhea]2%7
  19. Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]2%7
  20. No sign[no clinical sign was reported]2%7
  21. Pruritus[itching]2%7
  22. Uncoded sign[a sign with no matching dictionary term]2%7
  23. Ataxia[unsteady, uncoordinated movement]1.7%6
  24. Underfilling, Bottles[a product quality report, not a sign in an animal]1.7%6
  25. Ineffective, antiinflammatory[legacy FDA term: the product did not have the expected effect (antiinflammatory)]1.4%5
  26. Polyuria[passing more urine than usual]1.4%5
  27. Underfilling, Container[a product quality report, not a sign in an animal]1.4%5

Top 30 of 288 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal5.2%18
Recovered with Sequela0.3%1
Ongoing12.6%44
Died1.4%5
Euthanized0.3%1
Outcome Unknown12.6%44

What kind of report it was

Safety issue41.1%143
Lack of expected effectiveness1.4%5
Both safety and lack of expected effectiveness2.6%9
Manufacturing or product defect54.9%191
Other0%0

Coloured bar: reports naming dimethyl sulfoxide + fluocinolone acetonide. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Dog28.7%100
Human exposure10.6%37
Cat6%21
Other Birds0.3%1

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year1.1%4
1 to 3 years7.2%25
4 to 7 years8.3%29
8 to 11 years10.1%35
12 years and over14.1%49
Age not given59.2%206

Weight of the animal

Under 5 kg (11 lb)6.6%23
5 to 9.9 kg (11–22 lb)8%28
10 to 24.9 kg (22–55 lb)6.9%24
25 to 44.9 kg (55–99 lb)8.6%30
45 kg and over (99 lb+)1.1%4
Weight not given68.7%239

Route of administration stated in reports: auricular (otic) (56), topical (52), ophthalmic (30), intraocular (2), nasal (1), oral (1).

In context

MeasureDimethyl Sulfoxide + Fluocinolone AcetonideAll dog reportsAll reports
Reports348985,6751,357,245
Share of that pool's reports naming this drug—0%0%
Classed serious, of reports stating it49.1%38.3%38.6%
Death or euthanasia recorded, per 1,000 reports17.25563.8
Filed as lack of expected effectiveness (wholly or partly)4%—23%
Top term, share of reportsVials, Leaking 35.6%0%—

This set accounts for 98.9% of all reports naming fluocinolone acetonide, so no separate ingredient column is shown. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

Other ingredient sets sharing an ingredient

Active ingredientsReportsLatest 12 months
Dimethyl Sulfoxide371

Listed for navigation, ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another": drugs differ in formulation, in the animals they are given to, in sales volume and in years on the market. A report's ingredient field can be incomplete, so reports about one product may sit under more than one set.

FDA-approved products containing this combination (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

Trade nameActive ingredientsSponsorApproved forApplication
Synotic Otic SolutionDimethyl Sulfoxide, Fluocinolone AcetonideZoetis Inc.DogsNADA 045-512
Synsac SolutionDimethyl Sulfoxide, Fluocinolone AcetonideZoetis Inc.DogsNADA 047-334

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about dimethyl sulfoxide + fluocinolone acetonide reports

How many adverse event reports has FDA received for the combination dimethyl sulfoxide and fluocinolone acetonide?

348 reports record a drug with the combination dimethyl sulfoxide and fluocinolone acetonide as its active ingredients in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 12 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The Green Book lists 2 approved applications with this combination; the reference list on this page names them without any counts.

What signs are reported most often?

vials, Leaking (35.6%), accidental exposure (8.9%), caps, Abnormal (7.8%), seal, Abnormal (4.9%) and eye irritation (4.6%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

dog (28.7%), human exposure (10.6%) and cat (6%). Among single-breed animals the most frequent labels are Labrador Retriever, Domestic, Shih Tzu and Domestic Shorthair; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

12 reports in the 12 months to March 2026, up 200% from 4 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that dimethyl sulfoxide + fluocinolone acetonide harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of dimethyl sulfoxide + fluocinolone acetonide?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.